Reviewing Haleon (NYSE:HLN) and BioHarvest Sciences (NASDAQ:BHST)

BioHarvest Sciences (NASDAQ:BHST) and Haleon (NYSE:HLN) are both consumer staples companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.

Profitability

This table compares BioHarvest Sciences and Haleon’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioHarvest Sciences	-31.21%	-58.30%	-25.60%
Haleon	N/A	N/A	N/A

Insider & Institutional Ownership

6.7% of Haleon shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility & Risk

BioHarvest Sciences has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, Haleon has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500.

Valuation and Earnings

This table compares BioHarvest Sciences and Haleon”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioHarvest Sciences	$34.51 million	1.02	-$11.14 million	($0.52)	-3.46
Haleon	$14.54 billion	2.75	$2.20 billion	$0.39	23.24

Haleon has higher revenue and earnings than BioHarvest Sciences. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Haleon, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for BioHarvest Sciences and Haleon, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioHarvest Sciences	1	0	2	0	2.33
Haleon	1	5	2	2	2.50

BioHarvest Sciences presently has a consensus price target of $6.50, indicating a potential upside of 261.11%. Haleon has a consensus price target of $4.90, indicating a potential downside of 45.95%. Given BioHarvest Sciences’ higher probable upside, equities research analysts plainly believe BioHarvest Sciences is more favorable than Haleon.

Summary

Haleon beats BioHarvest Sciences on 11 of the 13 factors compared between the two stocks.

About BioHarvest Sciences

BioHarvest Sciences Inc. is a biotechnology company developing health and wellness products through its proprietary Botanical Synthesis technology. The platform is designed to produce plant-based compounds in controlled environments without relying on conventional agricultural cultivation of the whole plant, with the goal of preserving targeted botanical molecules and improving production consistency. The company’s primary commercial product is VINIA, a dietary supplement made from a proprietary red grape cell culture and marketed for its polyphenol content and potential cardiovascular and general wellness benefits.

About Haleon

Haleon plc is a global consumer healthcare company that develops and sells nonprescription health products. Its portfolio spans oral health, pain relief, vitamins and supplements, respiratory health, digestive health, and therapeutic skin care. Its brands include Sensodyne, parodontax and Polident in oral care; Advil, Panadol and Voltaren for pain relief; and Centrum, Emergen-C and Theraflu in supplements and respiratory care. Haleon sells its products in markets around the world. Haleon became an independent public company in 2022 after separating from GSK.